Skip to content

Unrelated cord blood transplantation after reduced toxicity conditioning with mesenchymal stromal cell co-infusion in patients with severe epidermolysis bullosa

Unrelated cord blood transplantation after reduced toxicity conditioning with mesenchymal stromal cell co-infusion in patients with severe epidermolysis bullosa - CB+MSCforEB

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON41470
Enrollment
11
Registered
2013-03-28
Start date
2013-11-01
Completion date
Unknown
Last updated
2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

butterfly child disease congenital bullous disease

Interventions

Reduced toxicity chemotherapy conditioning followed by cord blood transplantation with co-infusion of mesenchymal stromal cells for severe generalized recessive dystrophic EB

Sponsors

Universitair Medisch Centrum Utrecht
Lead Sponsor

Eligibility

Age
2 Years to 17 Years

Inclusion criteria

Inclusion criteria: (1) Diagnosed genetically & molecularly Epidermolysis Bullosa type recessive dystrofische severe generalized 2) having a single matching (* 5/6) umbilical CB unit available with sufficient cell count total NC count > 3 * E7/kg for the 8-10/10 matched units and >5*10e7/kg for the 6-7/10 matched units (3)Lansky,Karnofsky >40 (4)Age

Exclusion criteria

Exclusion criteria: (1) Creatinine clearance

Design outcomes

Primary

MeasureTime frame
Safety: Transplantation related mortality (TRM). Efficacy/Biology: Investigation of phenotype status post-transplantation by clinical assessment of chronic wound healing, blister provocation testing, and photographic documentation. We aim to use diagnostic laboratory techniques in order to assess presence of missing proteins at the dermal-epidermal junction after transplantation.

Secondary

MeasureTime frame
* Disease specific outcomes: Clinical blister assessment: Suction test (Electronic Diversities. U.S.A) & Rub test (Kiritsi et al, personal communication) * Acute GVHD ( Grade II-IV: Gluckberg Criteria) * Engraftment: Neutrophils > 500K/uL for 3 consecutive days and Platelet (day 180 > 50 K) engraftment. * Loss of CB chimerism (6 mths follow up). Event defined as: death, graft-failure (

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)